The investment fund sold $3.87 million worth of shares in the Argentine bank, reflecting a strategic portfolio adjustment as the lender navigates a challenging economic environment.
Robinhood Markets (HOOD) has captivated a generation of investors, but its soaring valuation and rich multiples are prompting some on Wall Street to sound the alarm for a potential correction.
As the U.S. renewable energy sector builds on a record-breaking 2025, it faces a critical juncture defined by supply chain pressures, extreme weather, and evolving market rules. Strategic adaptation, not just growth, will determine its sustainable trajectory.
Amidst market volatility, Microsoft's diversified empire—spanning cloud, AI, productivity, and gaming—positions it as a resilient long-term holding for investors looking beyond short-term fluctuations.
Once a high-flying green energy IPO, Plug Power now trades near historic lows. While its technology powers giants like Amazon and Walmart, mounting losses and a shifting political landscape pose existential questions about its path to profitability.
In a bold marketing move, telehealth company Hims & Hers is leveraging the Super Bowl's massive audience to spotlight healthcare inequality with its 'Rich People Live Longer' campaign. The push comes as the company expands into advanced diagnostics and treatments, while its stock navigates a significant valuation gap after recent volatility.
An Atlanta law firm is investigating Home Depot's planned layoff of nearly 800 Georgia workers, exploring a potential class-action lawsuit over whether the company violated federal notification laws.
Despite recent volatility in silver prices, Wheaton Precious Metals' unique streaming model positions it to generate robust cash flow, making it a standout choice for exposure to the precious metal.
Shareholders in Harley-Davidson's electric motorcycle spinoff, LiveWire Group, have seen their holdings erode dramatically over five years, with a recent $55 million weekly loss adding to the pain. The company's ongoing revenue contraction raises fundamental questions about its path to profitability in the competitive EV market.
Target's Michael Fiddelke and Walmart's John Furner step into the CEO role, outlining priorities to reinvigorate growth and customer loyalty amid operational and social challenges.
Meta Platforms' relentless investment in artificial intelligence infrastructure is set to drive capital expenditures to unprecedented levels in 2026, raising questions about long-term returns for the cash-rich tech giant.
Ark Invest's founder bolstered positions in key holdings across e-commerce, fintech, and cryptocurrency sectors ahead of major earnings reports, signaling confidence amidst market volatility.
The Schwab U.S. Dividend Equity ETF (SCHD) offers investors a balanced approach to generating income, targeting financially robust companies with a history of growing dividends. We examine its strategy, performance, and role in a portfolio.
Amid ongoing market volatility, financial professionals are urging middle-income households to steer clear of cryptocurrency investments, citing a toxic mix of extreme risk, lack of regulation, and the potential to derail long-term financial security.
Apple's acquisition of Israeli AI audio startup Q.ai signals a deeper push into biometric wearables, as the tech giant reportedly reshuffles its 2026 roadmap to prioritize premium iPhones—including a long-rumored foldable model—while navigating ongoing component shortages.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
While investors flock to mass-market and electric vehicle stocks, Ferrari's unique strategy of cultivating scarcity and brand prestige has delivered enviable margins and pricing power. With shares well off their highs, analysts debate if now is the time to buy into this iconic automaker for the long haul.
Despite posting blockbuster profits, Microsoft shares plunged 10% after its latest earnings, erasing hundreds of billions in market value. We examine whether Wall Street's reaction to cloud growth and AI spending fears is an overreaction or a prudent pause.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
